FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer

FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer  OncLiveNew RET Inhibitors Show Reduced Toxicities in Thyroid Cancer  MedscapeNew Breakthrough Therapy Designated for Thyroid Cancer and NSCLC  Cancer NetworkFull coverage

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Ei8Pma